← All trials
NCT04603690
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 15, 2020
- Primary completion
- May 14, 2021
- Completion date
- Jun 14, 2021
- First posted
- Oct 27, 2020
- Last posted
- Dec 10, 2020
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Liaquat University of Medical & Health SciencesLead sponsor
- Universidad de MurciaCollaborator
- Liaquat University of Medical & Health SciencesReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.